Zymeworks Inc. (ZYME)

USD 11.49

(2.13%)

Total Liabilities Summary of Zymeworks Inc.

Zymeworks Inc.'s latest annual total liabilities in 2023 was 116.07 Million USD , down -25.48% from previous year.
Zymeworks Inc.'s latest quarterly total liabilities in 2024 Q3 was 120.17 Billion USD , up 9.78% from previous quarter.
Zymeworks Inc. reported annual total liabilities of 155.76 Million USD in 2022, up 11.23% from previous year.
Zymeworks Inc. reported annual total liabilities of 140.03 Million CAD in 2021, up 9.02% from previous year.
Zymeworks Inc. reported quarterly total liabilities of 109.47 Million USD for 2024 Q2, down -5.43% from previous quarter.
Zymeworks Inc. reported quarterly total liabilities of 120.17 Billion USD for 2024 Q3, up 9.78% from previous quarter.

Annual Total Liabilities Chart of Zymeworks Inc. (2023 - 2014)

Historical Annual Total Liabilities of Zymeworks Inc. (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	116.07 Million USD	-25.48%
2022	155.76 Million USD	11.23%
2021	140.03 Million CAD	9.02%
2020	128.45 Million USD	4.84%
2019	122.52 Million USD	91.82%
2018	63.87 Million USD	311.37%
2017	15.52 Million USD	-81.73%
2016	84.99 Million USD	1631.02%
2015	4.91 Million USD	-54.97%
2014	10.9 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	115.75 Million USD	-0.28%
2024 Q2	109.47 Million USD	-5.43%
2024 Q3	120.17 Billion USD	9.78%
2023 Q1	127.2 Million USD	-18.34%
2023 FY	116.07 Million USD	-25.48%
2023 Q4	116.07 Million USD	-12.08%
2023 Q3	132.02 Million USD	-13.79%
2023 Q2	153.13 Million USD	20.38%
2022 Q4	155.76 Million USD	29.26%
2022 FY	155.76 Million USD	11.23%
2022 Q3	120.5 Million USD	-17.85%
2022 Q1	147.53 Million USD	5.35%
2022 Q2	146.68 Million USD	-0.57%
2021 FY	140.03 Million CAD	9.02%
2021 Q4	140.03 Million CAD	-0.98%
2021 Q3	141.43 Million USD	-6.01%
2021 Q1	112.91 Million USD	-12.1%
2021 Q2	150.48 Million USD	33.27%
2020 Q2	115.6 Million USD	1.26%
2020 Q4	128.45 Million USD	-7.83%
2020 Q1	114.15 Million USD	-6.83%
2020 Q3	139.36 Million USD	20.56%
2020 FY	128.45 Million USD	4.84%
2019 Q4	122.52 Million USD	35.37%
2019 Q3	90.51 Million USD	12.4%
2019 Q2	80.53 Million USD	17.95%
2019 Q1	68.27 Million USD	6.89%
2019 FY	122.52 Million USD	91.82%
2018 Q1	19.01 Million USD	22.43%
2018 Q2	24.53 Million USD	29.04%
2018 Q3	24.77 Million USD	0.98%
2018 Q4	63.87 Million USD	157.86%
2018 FY	63.87 Million USD	311.37%
2017 FY	15.52 Million USD	-81.73%
2017 Q4	15.52 Million USD	-9.44%
2017 Q3	17.14 Million USD	-2.67%
2017 Q2	17.61 Million USD	-80.21%
2017 Q1	89.03 Million USD	4.76%
2016 Q3	20.1 Million USD	0.0%
2016 Q1	- USD	-100.0%
2016 Q4	84.99 Million USD	322.77%
2016 FY	84.99 Million USD	1631.02%
2015 Q4	4.85 Million USD	0.0%
2015 FY	4.91 Million USD	-54.97%
2014 FY	10.9 Million USD	0.0%

Peer Total Liabilities Comparison of Zymeworks Inc.

Name	Total Liabilities	Total Liabilities Difference
ADC Therapeutics SA	503.03 Million USD	76.925%
Alto Neuroscience, Inc.	158.3 Million USD	26.675%
Annovis Bio, Inc.	17.95 Million USD	-546.324%
Biohaven Pharmaceutical Holding Company Ltd.	85.23 Million USD	-36.178%
Ginkgo Bioworks Holdings, Inc.	568.19 Million USD	79.571%
Nuvation Bio Inc.	16.36 Million USD	-609.412%
Nuvation Bio Inc.	16.36 Million USD	-609.412%
Arcus Biosciences, Inc.	633 Million USD	81.663%